Eli Lilly India has announced the launch of the additional indication for Ramiven (abemaciclib), following approval from The Drug Controller General of India (DCGI) in combination with endocrine therapy for adjuvant treatment in adult patients with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative, node-positive early breast cancer (EBC) at high risk of recurrence.
source https://www.pharmatutor.org/pharma-news/2022/eli-lilly-launches-ramiven-in-india
No comments:
Post a Comment